chartexchange

IBRX261106C00011000
IBRX Nov 6 2026 11.00 Call
optionOPRA

EODOct 16, 2026
0.45USD-18.182%(-0.10)34Vol379OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
11
Expiration
Nov 6, 2026
DTE
17d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.05-80.00%541,377
Oct 30, 202610d$0.25-28.57%232,025
Nov 6, 202617d$0.45-18.18%34379
Nov 13, 202624d$0.80-20.00%9437
Nov 20, 202631d$0.55-37.50%6305,863
Nov 27, 202638d$1.02+27.50%66
Dec 18, 202659d$1.35+0.00%3621
Jan 15, 202787d$1.15-32.35%39216,123
Mar 19, 2027150d$1.60-41.82%11921
Apr 16, 2027178d$2.48-0.80%198
May 21, 2027213d$3.00-3.23%1420
IBRX Nearby Strikes · Nov 6, 2026
StrikeLastChangeVolOpen IntMoneyness
8 C$1.85-31.23%10507ITM
8.5 C$2.20+37.50%44OTM
9 C$1.10-26.17%1864OTM
9.5 C$0.70-48.91%2235OTM
10 C$0.70-30.00%65125OTM
10.5 C$0.65-14.47%444OTM
11 C$0.45-18.18%34379OTM
11.5 C$0.35-38.60%239OTM
12 C$0.40-18.37%17307OTM
12.5 C$0.10-74.36%122OTM
13 C$0.43+22.86%733OTM
14 C$0.22-56.00%100145OTM
15 C$0.25+0.00%22OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.